TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05114525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: The survey questionnaire will include semi-structured questions about patient demographics and patient understanding of the risks and benefits of radiation, different treatment options, the treatment process, utility of visual aid presentation and information gathering preference using a semi-structured questionnaire
Study: NCT06245122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS23546
Description: Tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS23546
Description: Tablets administered orally.
Study: NCT04837859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients
Study: NCT05096208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF (Group 1)
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF (Group 2)
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF (Group 3)
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04859790

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Concerns Appraisal Retraining
Description: SCAR consists of an hour-long intervention session, followed by a 2-week-long EMI. During the hour-long intervention session, participants will receive psychoeducation (e.g., defining common terms like anxiety), discuss popular misconceptions they may have about publicly observable anxiety symptoms (e.g., people can tell I'm anxious by looking at me), and complete exposure exercises (e.g., practicing facing feared physical sensations such as sweating). During the EMI, participants will report on their social anxiety symptoms four times per day. When participants endorse elevated social anxiety during this time, they will receive a targeted message reminding them of the topics covered in the intervention session.
Study: NCT04759599

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy (SWL)
Description: Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock Wave Lithotripsy (SWL)
Description: Shock Wave Lithotripsy (SWL) with focal size 2mm (F1), and 3000 shocks or Shock Wave Lithotripsy (SWL) with focal size 8mm (F3), and 3000 shocks
Study: NCT05004688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
Description: Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10\^6 colony forming units (CFU) reconstituted in 0.1 mL saline.
Study: NCT06459050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dominant Limb Overcoming Isometric Conditioning Activity
Description: Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by the dominant limb.
Study: NCT05674591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: The CPT therapist will teach the patient about PTSD, depression, and anxiety, and outline the treatment regimen and rationale for its effectiveness. In the initial sessions, women will be asked to express their impact statements on the intimate partner violence to which they had been subjected. Women will be taught how to differentiate between events, thoughts, and emotions, as well as their interrelationships. Thoughts of self-blame and other misconceptions of the situation will be addressed using Socratic questioning. Women will be instructed on how to detect and counteract negative thoughts, as well as how to communicate more effectively. Women will be encouraged to evaluate negative thinking relating to five themes: safety, trust, power/control, self-esteem, and intimacy. During the final sessions, their impact statements on the violence to which they had been subjected will be altered to include emotional and cognitive insights obtained during the CPT.
Study: NCT05764876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Oral Tablet
Description: Oral tablet of linezolid 10mg/kg every 8 hours for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Oral Tablet
Description: Oral tablet of azithromycin 30mg/kg maximum 2gr single dose.
Study: NCT06482905

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
Description: Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
Description: Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
Description: Safety Run-In: Dose:6×10\^7 CAR+ T cells~Cohort A Single delivery route(Multi-dose)、Cohort B Dual delivery route(Multi-dose)： 3+3 dose escalation design： Dose Level 1: 6×10\^7 CAR+ T cells Dose Level 2: 1.5×10\^8 CAR+ T cells Dose Level 3: 2.5×10\^8 CAR+ T cells
Study: NCT06313489

Intervention type: PROCEDURE
Intervention: Biopsy of EPL tendon and muscle during the operation
Description: Biopsy of EPL tendon and muscle
Study: NCT05363319

Intervention type: DRUG
Intervention: Cemiplimab
Description: solution for injection via intravenous (IV) infusion

Intervention type: DRUG
Intervention: Cemiplimab
Description: solution for injection via intravenous (IV) infusion

Intervention type: DRUG
Intervention: Platinum-based chemotherapy
Description: IV administration
Study: NCT06471023

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP1
Description: Vitamin C formulation 1, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP1
Description: Vitamin C formulation 1, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP1
Description: Vitamin C formulation 1, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP2
Description: Vitamin C formulation 2, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP2
Description: Vitamin C formulation 2, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP2
Description: Vitamin C formulation 2, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP3
Description: Vitamin C formulation 3, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP3
Description: Vitamin C formulation 3, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP3
Description: Vitamin C formulation 3, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP4
Description: regular Vitamin C, 3000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP4
Description: regular Vitamin C, 3000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: TP4
Description: regular Vitamin C, 3000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: CP
Description: Vitamin C formulation 4, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: CP
Description: Vitamin C formulation 4, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: CP
Description: Vitamin C formulation 4, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: RP
Description: regular Vitamin C, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: RP
Description: regular Vitamin C, 1000 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: RP
Description: regular Vitamin C, 1000 mg
Study: NCT06311578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87704916
Description: JNJ-87704916 will be administered as an intratumoral injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87704916
Description: JNJ-87704916 will be administered as an intratumoral injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.
Study: NCT06459050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-dominant Limb Overcoming Isometric Conditioning Activity
Description: Each session involved performing 3 sets of 3-second overcoming isometric split squats with a 3-minute rest between sets as a conditioning activity performed by non-dominant limb.
Study: NCT06251635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5Mg Oral Tablet
Description: Olanzapine capsules (2.5mg) will be administered during one research visit for each menstrual cycle phase. The dosing schedule is as follows:~1. Day 0- 5mg~2. Day 1- 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5Mg Oral Tablet
Description: Olanzapine capsules (2.5mg) will be administered during one research visit for each menstrual cycle phase. The dosing schedule is as follows:~1. Day 0- 5mg~2. Day 1- 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule during one research visit of each menstrual cycle phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule during one research visit of each menstrual cycle phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro 100 UNT/ML
Description: At each visit, participants will be given an intranasal insulin challenge (160 IU) to assess brain insulin signalling via MRI based assay.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro 100 UNT/ML
Description: At each visit, participants will be given an intranasal insulin challenge (160 IU) to assess brain insulin signalling via MRI based assay.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: At each visit, participants will be given an intranasal saline placebo (1.6 mL) in order to establish baseline brain insulin signalling via MRI based assay.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: At each visit, participants will be given an intranasal saline placebo (1.6 mL) in order to establish baseline brain insulin signalling via MRI based assay.
Study: NCT05780177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Description: Participants in this arm will receive 4 sessions (20-60 minutes) of a brief behavioral treatment for insomnia called BBTI. Relaxation techniques are not a component of BBTI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT)
Description: Participants in this arm will receive 4 sessions (20-60 minutes) of progressive muscle relaxation training called PMRT.
Study: NCT05874427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimedia informed consent
Description: A standard consent form on paper to explain the procedure, with an additional video to explain the procedure and risks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard informed consent
Description: A standard consent form, written on paper, used to explain a procedure to a patient face-to-face by a physician.
Study: NCT04381689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ.
Description: Teratect Prefilled Syringe Inj. 0.5mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Tetra Pre-filled Syringe
Description: Fluarix Tetra Pre-filled Syringe 0.5mL
Study: NCT04560972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protein Phosphatase 2A Inhibitor LB-100
Description: Given IV
Study: NCT05169723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exertional respiratory activities
Description: participants will perform a series of exertional respiratory activities
Study: NCT06458582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula
Description: The intervention involves administering High-Flow Nasal Cannula therapy to very preterm infants immediately after birth.
Study: NCT05360160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNDX-5613
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO
Study: NCT05292989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty Assessment
Description: Personalised (tailored) approach that includes assessment of frailty and structured information provided to the consumer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard care practice
Study: NCT05169723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exertional respiratory activities
Description: participants will perform a series of exertional respiratory activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exertional respiratory activities
Description: participants will perform a series of exertional respiratory activities
Study: NCT05361941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EP Granules with Tobramycin
Description: EP Granules with Tobramycin is a Ca-salt resorbable intended for orthopedic applications as a bone void filler for bone gaps or voids and in cases where risk of post-operative infection is high, such as the first stage of a 2-stage or 1.5 stage revision of an infected total joint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: empty voids
Description: Voids are left empty
Study: NCT06100510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325mg
Description: Cohort B will receive one (1) 325 mg aspirin 24 hours prior to their second blood draw.
Study: NCT06509451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giomer pit and fissure sealant without etching
Description: S-PRG filler containig pit and fissure sealant without etching step

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giomer pit and fissure sealant with etching
Description: S-PRG filler containig pit and fissure sealant with etching step
Study: NCT06447350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Induced hypocrisy
Description: Induced hypocrisy task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social identity mapping
Description: Social identity mapping task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational modeling
Description: Motivational modeling task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: motivational interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: motivational interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational interviewing
Description: motivational interviewing
Study: NCT04655885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimization of cardiac flow by base water-electrolyte supply
Description: optimization of cardiac flow by base water-electrolyte supply of 1 ml / kg / h by Ringer Lactate® and faced with any decrease of more than 10% of the VES compared to the reference VES, achievement of an optimization of the preload by administration of 250 ml of Ringer Lactate® with renewal until correction of the VES.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control arm
Description: increase basic hydro-electrolyte supply of 6 ml / kg / h by Ringer Lactate® and 1: 1 blood loss compensation by crystalloids of the same nature.
Study: NCT05898659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABFnoS then ABFS (Cochlear implant)
Description: Cochlear implant with tonotopy-based fitting without synchronization with the contralateral hearing-aid then with synchronization with the contralateral hearing-aid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABFS then ABFnoS (Cochlear implant)
Description: Cochlear implant with tonotopy-based fitting with synchronization with the contralateral hearing-aid then without synchronization with the contralateral hearing-aid
Study: NCT06626152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apo-levocarb
Description: As above.
Study: NCT06688630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The laser acupuncture and artificial tears therapy
Description: Laser acupuncture therapy is the application of a Reimers \& Janssen LaserPen, with a power of 150mW and a wavelength of 810nm, alternating between Nogier frequencies A and C. The dosage is 2 joules per point, with a therapy duration of 26 seconds per point, targeting bilateral acupuncture points BL2, TE23, ST2, LI4, and ST36. The LaserPen is applied without pressing the laser probe onto the body surface.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: The sham laser acupuncture and artificial tears therapy
Description: Laser acupuncture therapy is a procedure using the same device but without activating the laser, so no energy is emitted. Performed at the same points as laser acupuncture therapy.~Artificial tears containing carboxymethylcellulose (CMC) will be used. The frequency of application is four times daily (morning, afternoon, evening, and night), with one drop per eye, administered to both eyes. Artificial tears will be used throughout the study duration (4 weeks). Use of any artificial tears other than CMC will be discontinued for 3 days and resumed on day 4 with CMC.
Study: NCT06081426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-ketogenic Diet
Description: Consuming a non-ketogenic diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-ketogenic Diet
Description: Consuming a non-ketogenic diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Consuming a ketogenic diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Consuming a ketogenic diet

Intervention type: OTHER
Group type: OTHER
Intervention: No diet
Description: Participants without Bipolar Disorder will not participate in the diet phases of the study
Study: NCT06718907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated stimuli
Description: Participants will be exposed to a video stimuli in order to assess biophysiological and physiological responses to the stressor and relaxant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management
Description: Participants will practice stress management and stress reduction at home, independently.
Study: NCT04974281

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PD-1 and Lenvatinib Plus TACE
Description: PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
Study: NCT06717698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide will be administered subcutaneously.
Study: NCT06723015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Description: Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection.~Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..